Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer
Frontiers in Pharmacology · 30.06.2026 · 17
DOI: 10.3389/fphar.2026.1878210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.06.2026. Verfasst von Guoxiang Rong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Affiliated Danyang Hospital of Nantong University, Danyang, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Porphyrin-based photosensitizers are widely used in photodynamic therapy (PDT) for A549 lung cancer. However, their clinical efficacy is limited by poor water solubility, the trade-off between fluorescence emission and singlet oxygen generation, and insufficient tumor targeting. To address these issues, researchers have turned to molecular design strategies. By constructing donor–acceptor systems and employing supramolecular assembly, they have significantly improved the photophysical properties of these photosensitizers. Building on these advances, smart delivery systems responsive to multiple tumor-specific stimuli, such as overexpressed matrix metalloproteinases, hypoxia, and acidic pH in the A549 tumor microenvironment, have been developed. These systems enable precise targeting and on-demand activation of the photosensitizer. To overcome the limitations of monotherapy, recent studies combine PDT with chemotherapy, starvation therapy, or ferroptosis. Such combinations enhance cancer cell killing through cascade amplification or mutual reinforcement mechanisms. In parallel, innovative delivery platforms, including engineered probiotics, cell membrane-derived vesicles, and all-API (active pharmaceutical ingredient) nanoparticles, have greatly improved tumor accumulation and biocompatibility of porphyrin photosensitizers. This review systematically integrates these recent advances, providing a solid foundation for the clinical translation of porphyrin-based photosensitizers in precision PDT for A549 lung cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Affiliated Danyang Hospital of Nantong University, Danyang, China.
- Medical School of Nantong University, Nantong, China.
- School of Pharmacy, Nantong University, Nantong, Jiangsu, China.
Zitieren
APA
Rong, G., Li, F., Li, T., Pan, H., Luo, X., & Zheng, X. (2026). Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1878210
Vancouver
Rong G, Li F, Li T, Pan H, Luo X, Zheng X. Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1878210
BibTeX
@article{Rong2026,
author = {Rong, Guoxiang and Li, Fengxi and Li, Ting and Pan, Huoying and Luo, Xuanxuan and Zheng, Xiaohua},
title = {Advances in porphyrin-based photosensitizers for photodynamic therapy of A549 lung cancer},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1878210}
}
EUVIMED